Search the Newsreel

Lazard Asset Management LLC Takes $1.66 Million Position in Xenia Hotels & Resorts, Inc. $XHR

Lazard Asset Management LLC recently acquired a new position in Xenia Hotels & Resorts, purchasing 111,662 shares valued at approximately $1.66 million. This move is part of broader institutional interest, with collective institutional ownership of the REIT standing at 92.43%. Analysts generally maintain a …

Earnings call transcript: Crexendo tops Q2 2026 profit view as shares rise

Crexendo Inc. reported strong Q2 2026 results, beating profit expectations with adjusted EPS of $0.12 and matching revenue forecasts at $24.65 million. The company saw a 49% revenue increase year-over-year, driven by the ESI acquisition, and reported its 12th consecutive quarter of GAAP profitability. …

Crexendo, Inc. Reports Q2 2026 Financial Results: Revenue Growth and Financial Highlights in Latest 10-Q Filing

Crexendo, Inc. reported its Q2 2026 financial results, showing a net income of $1.05 million and significant product revenue growth to $2.45 million, up from $1.20 million in Q2 2025. Despite increased revenue, net income and EPS declined year-over-year, while stockholders' equity and total …

Crexendo Q2 Earnings Call Highlights

Key Points Interested in Crexendo Inc.? Here are five stocks we like better. Strong Q2 growth: Revenue rose 49% year over year to $24.6 million, supported by telecom growth and the ESI acquisition. GAAP net income reached $1.1 million, while adjusted EBITDA increased 46% …

Xenon Pharmaceuticals Inc. $XENE Shares Bought by Sei Investments Co.

Sei Investments Co. significantly increased its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 160.8% in the first quarter, now owning 114,381 shares valued at approximately $6.65 million. Other institutional investors also adjusted their holdings, contributing to institutional and hedge fund ownership of 95.45% of …

Crexendo (CXDO) Surpasses Q2 Earnings Estimates

Crexendo (CXDO) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.09 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …

Crexendo, Inc. (NASDAQ: CXDO) grows revenue and completes $34,733 ESI deal

Crexendo, Inc. 2026: Revenue $14.87M, EPS $0.03— 10-Q Summary

Crexendo, Inc. reported its Q1 2026 results, showing a significant revenue increase of 77.5% year-over-year to $14.87M, primarily driven by the acquisition of ESI and organic subscriber growth. Despite revenue growth, net income and diluted EPS saw declines compared to the prior year quarter. …

Crexendo (CXDO) Releases Q2 2026 Earnings: Revenue Growth but EPS Miss

BRIEF-Crexendo Q2 Revenue USD 24.6 Million Vs. IBES Estimate USD 24.6 Million

Crexendo reported its Q2 revenue at USD 24.6 million, which matched the IBES estimate of USD 24.6 million. The article, originating from Reuters and distributed via TradingView, provides a brief financial update on the company's performance.

Xencor faces earnings test after revenue miss rocks biotech By Investing.com

Xencor, a clinical-stage biopharmaceutical company, is set to report its second-quarter results as investors seek signs of revenue recovery after a significant first-quarter miss. Analysts anticipate a loss of $0.81 per share on $17.51 million in revenue, an improvement from the previous quarter but …

Xencor (XNCR) Could Be 29% Undervalued Following Its Sharp Single Day Move

Xencor (XNCR) recently experienced a sharp single-day stock move

Nexxen International (NEXN) to Replace KPMG with EY for 2026 Audit

Nexxen International Ltd. has announced plans to replace KPMG with EY (Kost Forer Gabbay & Kasierer) as its independent registered public accounting firm for the fiscal year ending December 31, 2026. This change is contingent on shareholder approval at the 2026 Annual General Meeting. …

(XNCR) Risk Channels and Responsive Allocation

This article analyzes Xencor Inc. (XNCR) using AI models to identify strong sentiment across all horizons, supporting an overweight bias. It outlines three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along with multi-timeframe signal analysis …

Responsive Playbooks and the XENE Inflection

This article analyzes Xenon Pharmaceuticals Inc. (NASDAQ: XENE), highlighting weak near and mid-term sentiment but a strong long-term outlook. It details three AI-generated trading strategies—position, momentum breakout, and risk hedging—along with multi-timeframe signal analysis, indicating a favorable 36.9:1 risk-reward setup for a potential 10.9% …

Xenon Pharmaceuticals (XENE) to Release Earnings on Thursday

Xenia Hotels & Resorts Earnings Call Highlights Growth

Xenia Hotels & Resorts held its Q2 earnings call, reporting stronger operating performance, higher room rates, and an earnings beat on non-GAAP metrics, leading to raised full-year guidance for 2026. Despite positive RevPAR growth and strong demand trends, the company acknowledged margin pressures due …

Price to sales forward of Xenon Pharmaceuticals Inc. – NASDAQ:XENE

This article provides a brief financial update on Xenon Pharmaceuticals Inc. (NASDAQ: XENE), focusing on its forward price-to-sales ratio. It indicates that the market was closed at the time of publication with no trades. The content is primarily a data point from TradingView without …

XNCR|Xencor Inc|Price:20.220|Chg%:-1.270

This article provides a comprehensive stock analysis of Xencor Inc (XNCR), highlighting its stable fundamentals, significant growth potential, and "fairly valued" status. It notes high institutional ownership and multiple analyst "Buy" ratings with a target price of $29.64. The company, a clinical-stage biopharmaceutical firm, …

Xenon Sets $64.19 Option Price for 11 New Employees' Grants

Xenon Pharmaceuticals announced equity inducement grants for eleven new non-officer employees, effective July 30, 2026. The grants include 32,758 share options with an exercise price of $64.19 per common share and 19,013 restricted share units (RSUs). These awards, approved under Nasdaq Listing Rule 5635(c)(4), …

ETFs Investing in Xenia Hotels & Resorts, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Xenia Hotels & Resorts, Inc. (XHR). It provides a detailed table including each fund's market value, weight of XHR in the fund, issuer, management style, focus, expense ratio, assets under management (AUM), …

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

This article from Xenon Pharmaceuticals reports on inducement grants made under Nasdaq Listing Rule 5635(c)(4). The content provided is a security check, indicating further details are likely behind this initial gate.

Xenia Hotels & Resorts (XHR) Stock Climbs On Higher EBITDA Outlook And Debt Questions

Xenia Hotels & Resorts (XHR) saw its stock climb after management raised its full-year adjusted EBITDA guidance and reported stronger revenue per available room (RevPAR). While Q2 2026 showed a shift from profit to loss, the company's RevPAR increase, driven by higher average daily …

Should Xenia’s Q2 Loss and 2026 Guidance Cut Prompt Rethinking of Xenia Hotels & Resorts’ (XHR) Outlook?

Xenia Hotels & Resorts (XHR) reported a Q2 2026 net loss of US$19.34 million despite higher revenue, leading the company to cut its full-year guidance to a range of a US$6 million net loss to US$6 million net income. This updated outlook, influenced by …

Price to cash flow ratio of Xenon Pharmaceuticals Inc. – HAM:XP0

This article displays financial information for Xenon Pharmaceuticals Inc. (HAM:XP0), specifically its price to cash flow ratio. It notes that the market is closed and no trades have occurred for this stock. The content primarily focuses on the company's financial overview within the TradingView …

Xencor Secures Ultomiris Royalty Settlement Payment

Xencor announced a settlement agreement with Alexion Pharma International Operations regarding U.S. royalties on Ultomiris, securing $105 million in two installments. This agreement eliminates Alexion’s future U.S. royalty obligations while preserving ex-U.S. royalties. The capital effectively replaces anticipated U.S. royalty income through 2028, extending …

Vanguard Capital Management (XNCR) discloses 3.8M-share, 5.13% stake in Xencor

Vanguard Capital Management has disclosed a 5.13% passive stake in Xencor Inc. (XNCR), holding 3,810,823 shares of common stock. This ownership is reported across various Vanguard funds and managed accounts, with Vanguard exercising sole voting power over 532,021 shares and sole dispositive power over …

From intern to CTO: Chris Aaker set to lead Crexendo technology

Crexendo (NASDAQ: CXDO) has appointed Chris Aaker as Chief Technology Officer, effective August 1, 2026, as part of a planned leadership succession. Aaker, who started as an intern and has nearly two decades of experience with NetSapiens and Crexendo, will lead technology innovation. Current …

Xenia Hotels & Resorts Inc earnings missed by $0.43, revenue fell short of estimates

Xenia Hotels & Resorts Inc (NYSE: XHR) reported second-quarter EPS of $-0.21, significantly missing analyst estimates of $0.22 by $0.43. The company's revenue for the quarter was $295.49 million, also falling short of the consensus estimate of $301.37 million. Despite the earnings miss, Xenia …

Xenon Pharmaceuticals Inc (XENE) Financial Health: Profitability & Balance Sheet Analysis

Xenon Pharmaceuticals Inc (XENE) has a current financial score of 6.41, ranking 249 out of 384 in the Biotechnology & Medical Research industry, indicating robust financial status but low operating efficiency. The company's latest quarterly revenue saw a 100% year-over-year decrease, and its net …

Xenia Hotels & Resorts Declares Second Quarter Dividend of $0.14 Per Share>XHR

Xenia Hotels & Resorts (NYSE: XHR) has declared a cash dividend of $0.14 per share for the second quarter of 2026. This dividend is payable on July 31, 2026, to shareholders of record as of July 15, 2026. The announcement reflects the company's commitment …

Xenon to Report Q2 2026 Financial Results on August 6, 2026

Xenon Pharmaceuticals Inc. announced it will report its second-quarter 2026 financial results and provide a business update on Thursday, August 6, 2026, after the close of U.S. financial markets. The company, focused on neuroscience, will host a webcast and conference call to discuss its …

Xencor (XNCR) Reiterated by Wedbush -- Rating Maintained at Outp

Wedbush has reiterated its Outperform rating for Xencor (XNCR) with a maintained price target of $26.00, reflecting confidence in its future performance. However, GuruFocus's GF Value™ indicates the stock is significantly overvalued at $19.91 compared to its intrinsic value of $9.13, and its GF …

Xenia Hotels & Resorts Sees FY Loss $6M-Net $6M >XHR

Xenia Hotels & Resorts (XHR) is forecasting a full-year net loss of $6 million, as indicated by their recent financial outlook. This announcement provides key financial guidance for investors regarding the company's expected performance.

Crexendo Inc (CXDO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Crexendo Inc (CXDO), focusing on its support and resistance levels, various technical indicators, and moving averages. It reveals that CXDO's price momentum score is 5.17, and the stock is trading between a resistance level of $8.29 and …

RBC Capital Maintains Nexxen International(NEXN.US) With Buy Rating, Maintains Target Price $11

RBC Capital has reiterated its Buy rating for Nexxen International (NEXN.US) and maintained its target price at $11. This indicates a continued positive outlook on the company's stock performance by the firm.